Keeping tabs on this stock: Seneca Biopharma, Inc. (SNCA) rushed in the after-market trading

ORC Stock
ORC Stock

Seneca Biopharma, Inc. (Nasdaq: SNCA), shares soared 11.5% to $0.89 in the AH trading session as the biopharmaceutical corporation devoted to producing new therapies for conditions of high medical need, recently published its financial results for the quarter ended 30 September 2020.

On September 30, 2020, cash was approximately $12.7 million compared to approximately $15.8 million on June 30, 2020.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Operating loss for the three-month period ended September 30, 2020, was $2.3 million instead of a loss of $2.1 million for the corresponding period in 2019. For the nine-month period ended September 30, 2020, the operating loss was $6.3 million vs. $6.5 million last year.

As the company continues to wind down the clinical trials, the decrease in operating loss for 2020 was primarily because of lower R&D expenses. Compared to the same period in the previous year, this decrease was partially offset by an increase in G&A expenses resulting from the improved management structure.

It posted a net loss of $2.3 million, or $0.13 per share, for the third quarter ended September 30, 2020, compared to a loss of $1.8 million, or $0.59 per share, for the same quarter in 2019.

Over the same period in 2019, the company lost $6.3 million, or $4.80 per share, while in 2020, it lost $11.8 million, or $0.93 per share. This rise in net loss was attributed primarily to the January 2020 warrant inducement transaction, which generated a non-cash expense of $5.6 million.


Please enter your comment!
Please enter your name here